Stockreport

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire Ch...

CASI Pharmaceuticals, Inc. - Ordinary Shares  (CASI) 
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations
PDF in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational [Read more]